95 Bristol-Myers Squibb cyclists set off on a 3,600km journey across Europe for cancer research

C2C4C Bikers riding uphill
10 September 2019

Cancer is among the leading causes of death worldwide with 18.1 million new cases and 9.6 million cancer-related deaths worldwide in 2018, and these numbers are growing. 

This is why for the fourth year running, Bristol-Myers Squibb, a global biopharmaceutical company, has chosen to support the Union for International Cancer Control (UICC) and its members by raising funds for the fight against cancer.

After the huge success of the last three editions of the European Country 2 Country 4 Cancer ride (C2C4C), where over 324,000 USD has been raised for cancer research and patient support, 95 Bristol Myers Squibb employees from across Europe are again cycling over 3,600km from Germany to the UK. Along this impressive route, they will ride through Switzerland, Italy, France, and Spain in an effort to raise funds for cancer research and organisations that support cancer patients in Europe. Each of the organisations benefiting from the ride are members of the Union for International Cancer Control.

95 European Bristol-Myers Squibb employees set off from Munich, Germany on Monday 9 September, and will ride in six different country teams with each group performing one leg of the ride averaging a total of 720km cycled in 3 days. The journey will last for 18 days and will finish in London on the 27 September 2019.

C2C4C bikers cheering

The participants are novice riders, who have committed themselves to 5 months of intensive training to complete their portion of the ride. Some are cancer survivors, others have witnessed the devastating impact of cancer on friends and family. All are dedicated Bristol-Myers Squibb employees and are riding for the fight against cancer.

Show your support and encourage your colleagues, friends and family to do the same by donating here.

To keep up to date with the riders and their journey follow us on social media @uicc and use the hashtag #C2C4C.

 
Last update: 
Friday 27 September 2019
Share